GSK plc American Depositary Shares (Each representing two Ordinary Shares)

Notable Price Movement

1. Aug 3-7$52.962.46%

   GSK fell $2.18, or 4.06%, from $53.71 to $51.53 over the supplied trading interval. The stock declined in four consecutive sessions from July 28 through August 3, including a $1.15 drop on July 30, before edging up $0.02 on August 4. The supplied evidence includes GSK’s strategic collaboration with Relation Therapeutics to use artificial intelligence in drug discovery and strengthen its early-stage pipeline, with reports citing either $100 million or $110 million of potential value, but it does not establish that the agreement drove the shares. No earnings or other company-specific catalyst explains the decline. The broader healthcare sector had an eventful week, although no market-wide performance data were supplied.

   5 sources

Stories & Analysis

A No to BMS can open doors for a Yes to GSKmarketscreener.com · 1d agoGSK shares rally on parent company news and retail momentum; other pharma firms followEnterpriseAM · 2d agoGSK plc (GSK) president reports acquisition of notional ADS in savings planStock Titan · 2d agoREG - GSK PLC - Director/PDMR ShareholdingTradingView · 2d agoGSK plc (LON:GSK) Receives Average Recommendation of "Hold" from AnalystsMarketBeat · 2d agoWhy (GSK) Price Action Is Critical for Tactical TradingStock Traders Daily · 3d agoHalozyme Gains Higher Q2 Profit Alongside Collaboration Deals; Ups 2026 GuidanceRTTNews · 3d agoEmma Walmsley | Former GSK CEO & British Business ExecutiveEncyclopedia Britannica · 6d ago